1Keam B,Im SA,Han SW,et al.Modified FOLFOX-6 chemotherapy in ad-vanced gastric cancer:results of phaseⅡstudy and comprehensive analy-sis of polymorphisms as a predictive and prognostic marker(J).BMC Cancer,2008;27(5):148-58.
2Folkman J.Role of angiogenesis in tumor growth and metastasis(J).Se-min Oncol,2002;29(6 Suppl 16):15-8.
3Standker L,Schrader M,Kanse SM,et al.Isolation and characterization of the circulating from of human endostatin(J).FEBS Lett,1997;420:129-33.
4Kim YM,Hwang S,Kim YM,et al.Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction KSR/Flk-1(J).Biol Chem,2002;277:27872-9.
8Folkman J.Role of angiogenesis in tumor growth and metastasis[J].Semin Oncol,2002,29(6 Suppl 16):15-18.
9Folkman J.Anti-angiogenesis in cancer therapy-endostatin and its mechanisms of action[J].Expt Cell Res,2006,312:594-607.
10Robert FO,Herbst RS,Colson YL,et al.Clinical cancer advances 2006:major research advances in cancer treatment,prevention,and screening-a report from the american society of clinical oncology[J].J Clin Oncol,2007,25(1):1-17.
8Van Meter ME,Kim Es. Bevacizumab:Current updates in treatment[J]. Curr Treatment Options Oncol, 2010,22 (6) : 586-591.
9Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs FOL- FOX4 as first-line therapy for metastatic colorectal can eer:NO 16966 updated results[J]. Br J Cancer,2011,105 (1) :58-64.
10Gravalos C, Salut A, Garcia-Gir6n C, et al. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leuco- vorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer[J]. Clin Transl Oncol, 2012, 14(8):606-612.
